Key facts
- Genegrow’s last known valuation is $34.6M (Apr 2024).
- It has raised $4.2M; the latest was Early Stage VC in Aug 2025.
- Notable investors include Jinding Capital, Dalton Venture, HaiBang Ventures, Zhejiang Silicon Paradise Asset Management Group, Shanghai Lingang Economic Development.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Genegrow
- ·The full record, as it builds
Funding rounds
No funding rounds for Genegrow are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Genegrow
Manufacturer of synthetic biology-based functional ingredients aims to drive innovation in biomanufacturing. The company's offerings feature advanced R&D in plant cells and biological strains, high-performance functional ingredient development, and large-scale production and sales capabilities, helping customers in pharmaceuticals, cosmetics, food, and related industries benefit from sustainable, high-value solutions, enabling improved product performance and industrial upgrading.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2023
- Employees
- 60
- Website
- genegrow.bio/
- Ownership
- Privately Held (backing)
Genegrow doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Genegrow shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Genegrow in its N-PORT filings yet. We sweep new filings monthly.